Ole Ahlehoff

Ole Ahlehoff

Auto-generated profile, based on publicly available information

Ole Ahlehoff

Department of Cardiology, The Heart Centre, Copenhagen University Hospital, Rigshospitalet , Copenhagen , Denmark

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MEMohamad El-Chouli
Mohamad El-Chouli
AMAlessandra Meddis
Alessandra Meddis
DCDaniel M Christensen
Daniel M Christensen
TGThomas A Gerds
Thomas A Gerds
TSThomas Sehested
Thomas Sehested
GGGunnar Gislason
Gunnar Gislason
Aims: In a continuously ageing population of patients with congenital heart disease (CHD), understanding the long-term risk of morbidity is crucial. The aim of this study was to compare the lifetime risks of developing comorbidities in patients with simple CHD and matched controls.Methods and results: Using the Danish nationwide registers spanning from 1977 to 2018, simple CHD cases were defined as isolated atrial septal defect (ASD), ventricular septal defect (VSD), pulmonary stenosis, or patent ductus arteriosus in patients surviving until at least 5 years of age. There were 10 controls identified per case. Reported were absolute lifetime risks and lifetime risk differences (between patients with simple CHD and controls) of incident comorbidities stratified by groups and specific cardiovascular comorbidities. Of the included 17 157 individuals with simple CHD, the largest subgroups were ASD (37.7%) and VSD (33.9%), and 52% were females. The median follow-up time for patients with CHD was 21.2 years (interquartile range: 9.4–39.0) and for controls, 19.8 years (9.0–37.0). The lifetime risks for the investigated comorbidities were higher and appeared overall at younger ages for simple CHD compared with controls, except for neoplasms and chronic kidney disease. The lifetime risk difference among the comorbidity groups was highest for neurological disease (male: 15.2%, female: 11.3%), pulmonary disease (male: 9.1%, female: 11.7%), and among the specific comorbidities for stroke (male: 18.9%, female: 11.4%). The overall risk of stroke in patients with simple CHD was mainly driven by ASD (male: 28.9%, female: 17.5%), while the risks of myocardial infarction and heart failure were driven by VSD. The associated lifetime risks of stroke, myocardial infarction, and heart failure in both sexes were smaller in invasively treated patients compared with untreated patients with simple CHD.Conclusion: Patients with simple CHD had increased lifetime risks of all comorbidities compared with matched controls, except for neoplasms and chronic kidney disease. These findings highlight the need for increased attention towards early management of comorbidity risk factors.

1 November 2014 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
SKSøren Lund Kristensen
Søren Lund Kristensen
OAOle Ahlehoff
Ole Ahlehoff
JLJesper Lindhardsen
Jesper Lindhardsen
RERune Erichsen
Rune Erichsen
MLMorten Lamberts
Morten Lamberts
PHPeter Riis Hansen
Peter Riis Hansen
Background—: Inflammatory bowel disease (IBD) is associated with increased cardiovascular risk. We examined the effect of active IBD on major adverse cardiovascular outcomes after myocardial infarction (MI). Methods and Results—: In nationwide registries, we identified 86 790 patients with first-time MI from the period 2002 to 2011. A total of 1030 patients had IBD, and we categorized their disease activity stages into either flare (120 days), persistent (>120 days) activity, or remission. Short-term mortality was estimated in a logistic regression-model, whereas risk of recurrent MI, all-cause mortality, and a composite of recurrent MI, cardiovascular death, and stroke were estimated by Cox regression-models. Odds ratio of death during hospitalization or within 30 days of discharge (n=13 339) corresponded to 3.29 (95% confidence interval [CI], 1.98–5.45) for patients in IBD flares, 1.62 (95% CI, 0.95–2.77) for persistent activity, and 0.97 (95% CI, 0.78–1.19) for remission when compared with the non-IBD group. Among 73 451 patients, including 863 with IBD, alive 30 days after discharge, IBD was associated with hazard ratios of 1.21 (95% CI, 0.99–1.49) for recurrent MI, 1.14 (95% CI, 1.01–1.28) for all-cause mortality, and 1.17 (95% CI, 1.03–1.34) for the composite end point. When compared with the non-IBD group, IBD flares, in particular, were associated with increased risks of recurrent MI (hazard ratio, 3.09; 95% CI, 1.79–5.32), all-cause mortality (hazard ratio, 2.25; 95% CI, 1.61–3.15), and the composite end point (hazard ratio, 2.04; 95% CI, 1.35–3.06), whereas no increased risk was identified in remission. Conclusions—: Active inflammatory bowel disease worsens prognosis after MI, in particular, in relation with flares.

13 June 2014 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
OAO. Ahlehoff
O. Ahlehoff
GGG. Gislason
G. Gislason
MLM. Lamberts
M. Lamberts
FFF. Folke
F. Folke
JLJ. Lindhardsen
J. Lindhardsen
PHPeter Riis Hansen
Peter Riis Hansen
Objectives: Psoriasis is a chronic inflammatory disease that is associated with a prothrombotic state and cardiovascular disease, including atrial fibrillation and thromboembolism. We therefore evaluated the impact of psoriasis in patients with atrial fibrillation and the performance of the CHA2DS2VASc score in these patients.Design, setting and participants: The study comprised all Danish patients hospitalized with nonvalvular atrial fibrillation in the period 1997–2011 (n = 99 357). Follow‐up started 7 days from discharge and excluded subjects treated with anticoagulation. Poisson regression adjusted for CHA2DS2VASc score was used to estimate the incidence rate ratios and 95% confidence intervals.Main outcome measure: Hospitalization or death from thromboembolism.Results: Mean follow‐up was 3.5, 3.1, and 2.8 years for patients with no psoriasis, mild psoriasis and severe psoriasis, respectively. Patients with psoriasis were younger compared to patients without psoriasis, but CHA2DS2VASc score did not differ between the three groups. Thromboembolism rates per 100 patient‐years (95% confidence intervals) were 4.8 (4.7–4.9), 4.8 (4.2–5.4) and 6.1 (5.0–7.5) for patients with no psoriasis, mild psoriasis and severe psoriasis, respectively. Importantly, the observed thromboembolism rates in patients with severe psoriasis were markedly higher (2.6‐ to3.4‐fold) than predicted by the CHA2DS2VASc score. Relative to no psoriasis, incidence rate ratios were 0.99 (0.87–1.11) and 1.27 (1.02–1.57) for mild and severe psoriasis, respectively. Correspondingly, incidence rate ratios for fatal stroke were 0.97 (0.80–1.12) and 1.51 (1.12–2.05).Conclusions: In patients with nonvalvular atrial fibrillation not treated with oral anticoagulation, severe psoriasis was associated with increased risk of thromboembolism. In these patients, CHA2DS2VASc underestimated the risk of thromboembolism.

1 May 2016 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
PDF file
UKUsman Khalid
Usman Khalid
AEAlexander Egeberg
Alexander Egeberg
OAOle Ahlehoff
Ole Ahlehoff
LSLaerke Smedegaard
Laerke Smedegaard
GGGunnar Hilmar Gislason
Gunnar Hilmar Gislason
PHPeter Riis Hansen
Peter Riis Hansen
Objective— Abdominal aortic aneurysm (AAA) is a complex multifactorial disease associated with a high morbidity and mortality. Increased inflammation including T-helper 17 cell–mediated effects has been implicated in AAA pathogenesis. Psoriasis is considered to be a T-helper 17-driven chronic inflammatory disease and in view of potentially overlapping inflammatory mechanisms, we investigated the risk of AAA in patients with psoriasis in a nationwide cohort. Approach and Results— The study comprised all Danish residents aged ≥18 years followed up from January 1, 1997, until diagnosis of AAA, December 31, 2011, migration or death. Information on comorbidity, concomitant medication, and socioeconomic status was identified by individual-level linkage of administrative registers. Incidence rates for AAA were calculated and incidence rate ratios adjusted for age, sex, comorbidity, medications, socioeconomic status, and smoking were estimated in Poisson regression models. A total of 5 495 203 subjects were eligible for analysis. During the study period, we identified 59 423 patients with mild psoriasis and 11 566 patients with severe psoriasis. The overall incidence rates of AAA were 3.72, 7.30, and 9.87 per 10 000 person-years for the reference population (23 696 cases), mild psoriasis (240 cases), and severe psoriasis (50 cases), respectively. The corresponding adjusted incidence rate ratios for AAA were increased in patients with psoriasis with incidence rate ratios of 1.20 (95% confidence interval, 1.03–1.39) and 1.67 (confidence interval, 1.21–2.32) for subjects with mild and severe disease, respectively. Conclusions— In a nationwide cohort, psoriasis was associated with a disease severity-dependent increased risk of AAA. The mechanisms and consequences of this novel finding require further investigation.